sebastian
l
johnston
search
cure
common
cold
inde
reason
effect
treatment
focu
intens
research
far
without
encourag
result
chief
obstacl
success
treatment
enorm
number
microorgan
associ
syndrom
differ
virus
atyp
bacteria
see
tabl
problem
diagnosi
exampl
recent
import
rhinono
effect
treatment
common
cold
yet
develop
combin
antivir
antiinflammatori
therapi
best
hope
intervent
onset
symptom
prophylaxi
especi
form
vaccin
would
major
impact
diseas
prevent
approach
offer
new
avenu
treat
popul
risk
particular
signific
asthma
chronic
bronchiti
sl
johnston
virus
appreci
method
avail
earlier
epidemiolog
studi
adequ
detect
obstacl
includ
rapid
mutat
rate
virus
lead
emerg
drugresist
strain
toxic
mani
type
drug
difficulti
drug
deliveri
vaccin
develop
problem
expens
efficaci
implement
unwant
effect
includ
increas
diseas
sever
problem
persuad
mani
pharmaceut
compani
abandon
research
programm
howev
renew
interest
advanc
made
possibl
molecular
biolog
techniqu
promis
area
futur
progress
vaccin
design
intervent
strategi
direct
increas
knowledg
genet
makeup
protein
structur
virus
involv
atyp
bacteria
mycoplasma
pneumonia
chlamydia
pneumonia
year
round
autumn
spring
peak
year
round
winter
peak
epidem
year
round
winter
peak
discret
yearli
winter
epidem
sporad
sporad
fiveyearli
epidem
cycl
new
organ
true
incid
uncertain
aeach
agent
review
ref
bvariabl
incid
depend
age
immun
season
common
cold
probabl
frequent
ill
afflict
humankind
certainli
main
caus
consult
primarycar
medic
practition
develop
world
also
associ
signific
industri
school
absente
base
current
estim
adult
thought
averag
five
ill
per
annum
schoolag
children
ill
per
annum
infant
probabl
suffer
frequent
numer
factor
influenc
epidemiolog
upper
respiratori
tract
viral
infect
includ
individu
commun
immun
season
variat
smoke
psycholog
stress
socioeconom
factor
nutrit
popul
densiti
perhap
importantli
famili
structur
well
known
preschool
schoolag
children
frequent
rout
new
virus
introduc
famili
addit
common
cold
upper
respiratori
tract
viral
infect
associ
moresever
diseas
particularli
presenc
signific
diseas
viru
infect
associ
mani
exacerb
asthma
children
exacerb
adultsl
common
complic
includ
otiti
media
sinus
although
detail
epidemiolog
studi
yet
carri
accur
quantifi
risk
individu
agent
symptom
common
cold
princip
involv
rhinorrhoea
result
vascular
leakag
later
mucou
secret
nasal
blockag
chiefli
result
mucos
oedema
consequ
upon
vascular
engorg
inflammatori
cell
infiltr
sore
throat
probabl
result
part
inflammatori
mediat
releas
also
common
symptom
sever
studi
look
inflammatori
mediat
upper
respiratori
tract
infect
kinin
histamin
atop
subject
leukotrien
ref
detect
nasal
secret
recent
sever
cytokin
includ
interleukin
interleukin
interleukin
interleukin
tumour
necrosi
factor
interferon
x
interferon
well
chemokin
rant
regul
upon
activ
normal
texpress
secret
macrophag
inflammatori
protein
l
x
found
nasal
secret
subject
common
cold
neutrophil
infiltr
peripher
blood
leucopenia
long
recogn
upper
respiratori
tract
infect
levandowski
demonstr
elev
number
lymphocyt
nasal
secret
use
flow
cytometri
howev
studi
nasal
biopsi
fail
demonstr
mucos
lymphocytosi
common
cold
may
technic
problem
time
biopsi
sampl
inflammatori
cell
infiltr
directli
import
produc
nasal
congest
contrast
lower
airway
recent
demonstr
lymphocyt
infiltr
bronchial
mucosa
normal
subject
undergo
experiment
nasal
rhinoviru
infect
eosinophil
eosinophil
product
eosinophil
cation
protein
major
basic
protein
also
implic
virusassoci
wheez
episod
also
demonstr
bronchial
mucos
eosinophilia
experiment
cold
normal
asthmat
subject
tm
mani
therapi
common
cold
tri
although
none
success
far
recent
review
claim
consum
vitamin
c
reduc
durat
ill
averag
inhal
humidifi
hot
air
shown
reduc
sever
symptom
zinc
glucon
also
shown
reduc
symptom
durat
day
mechan
unknown
although
possibl
antivir
effect
howev
treatment
studi
neg
result
thu
treatment
suffici
effect
gain
widespread
accept
specif
avenu
treatment
summar
fig
nasal
ifn
z
first
test
year
ago
probabl
success
treatment
use
undoubtedli
effect
given
shortli
exposur
viru
also
given
prophylact
contact
famili
outbreak
howev
owe
sever
drawback
includ
expens
product
frequenc
dosag
problem
local
bleed
discharg
gain
favour
pharmaceut
compani
clinician
specif
viru
antagonist
current
licens
use
princip
activ
influenza
type
amantidin
rimantidin
respiratori
syncyti
viru
rsv
ribavarin
amantidin
discov
acycl
amin
wherea
rimantidin
methyl
deriv
cross
bloodbrain
barrier
therefor
possess
properti
induc
jitteri
sometim
associ
amantidin
compound
thought
act
viruscel
attach
uncoat
probabl
interf
ion
flux
mediat
protein
amantidin
rimantidin
effect
influenza
type
recommend
use
presenc
clear
virolog
epidemiolog
evid
influenza
infect
commun
use
prophylact
week
atrisk
popul
elderli
chronic
afflict
eg
asthma
chronic
bronchiti
within
commun
group
whether
vaccin
therapi
initi
first
h
symptom
given
ten
day
drug
replac
vaccin
inact
influenza
type
b
ribavarin
nucleosid
analogu
activ
rsv
vivo
also
influenza
herpesvirus
vitro
mechan
action
unknown
evid
interfer
protein
translat
mrna
possibl
interf
cap
ribavarin
rel
toxic
use
therefor
restrict
aerosol
infant
children
within
first
three
day
rsv
bronchiol
major
obstacl
widespread
use
antivir
therapi
specif
specif
antivir
therapi
need
use
context
rapid
viral
diagnosi
major
agent
especi
common
rhinovirus
coronavirus
present
avail
diagnost
method
inadequ
howev
develop
polymeras
chain
reaction
pcr
viral
diagnosi
may
make
earli
diagnosi
appropri
specif
treatment
possibl
futur
tm
except
influenza
type
epidem
rsv
bronchiol
treatment
given
blind
knowledg
rhinovirus
respons
cold
made
particularli
attract
target
therapi
thu
mani
compound
studi
inhibit
rhinovir
infect
prevent
viru
uncoat
viru
entri
cell
inhibit
variou
stage
viru
replic
viru
gain
entri
cell
tabl
mani
studi
mention
individu
suffic
say
fact
effect
drug
emerg
far
result
combin
factor
import
limit
drug
potenc
deliveri
drug
toxic
virus
depend
host
cell
machineri
reproduc
compound
toxic
virus
toxic
human
emerg
drugresist
virus
micrc
bioiogi
vaccin
develop
long
thought
potenti
effect
way
control
virusinduc
diseas
vaccin
develop
programm
respiratori
virus
littl
success
nevertheless
kill
whole
split
viru
influenza
vaccin
effect
despit
antigen
drift
requir
intens
vigil
annual
revaccin
rsv
prioriti
vaccin
product
major
setback
occur
subsequ
natur
exposur
viru
formalininactiv
vaccin
found
associ
increas
morbid
mortal
consider
research
undertaken
determin
advers
effect
result
vaccin
review
recent
ref
present
thought
suggest
differ
rsv
protein
capabl
induc
differ
cellular
immun
respons
f
protein
produc
thltype
respons
increas
product
cytolyt
activ
g
protein
favour
respons
increas
eosinophilia
decreas
viral
clearanc
clinic
studi
f
subunit
vaccin
way
hope
safe
effect
vaccin
horizon
initi
trial
also
carri
parainfluenza
type
vaccin
recent
progress
vaccin
type
review
extens
elsewher
respiratori
virus
command
rel
littl
attent
particular
rhinovirus
difficult
target
vaccin
design
differ
serotyp
specif
induct
neutral
antibodi
recent
work
howev
suggest
tcell
respons
rel
conserv
across
serotyp
may
fruit
area
futur
research
corticosteroid
known
widespread
antiinflammatori
effect
includ
reduct
inflammatori
cell
infiltr
cytokin
product
effect
assess
random
control
trial
although
one
studi
show
reduc
inflamm
symptom
first
two
day
treatment
appear
rebound
effect
treatment
stop
overal
benefit
demonstr
second
recent
studi
compar
oral
prednisolon
placebo
experiment
rhinoviru
infect
steroid
report
reduc
sneez
mucu
weight
first
day
overal
differ
symptom
steroid
even
associ
increas
viral
titr
use
high
dose
oral
steroid
common
cold
justifi
view
known
side
effect
howev
steroid
may
effect
logic
place
treatment
virusassoci
wheez
ill
sever
recent
studi
use
inhal
steroid
virusassoci
wheez
children
vari
age
highdoseinh
steroid
use
immedi
onset
upper
lower
respiratori
symptom
shown
partial
benefit
although
benefit
shown
studi
use
lower
dose
prophylact
therapi
although
earli
studi
fail
show
elev
histamin
level
common
cold
recent
studi
found
increas
particularli
among
atop
subjectsl
howev
antihistamin
treatment
common
cold
shown
littl
benefit
sinc
studi
morepot
nonsed
antihistamin
introduc
interestingli
one
loratadin
appear
reduc
epitheli
cell
intercellular
adhes
molecul
express
given
role
inflamm
role
cellular
receptor
rhinovirus
would
interest
reassess
compound
particularli
virusinduc
wheez
episod
elev
level
kinin
also
found
associ
natur
experiment
cold
howev
one
trial
bradykinin
antagonist
carri
unfortun
neg
result
although
studi
morepot
bradykinin
antagonist
await
anticholinerg
nasal
spray
shown
reduc
rhinorrhoea
sneez
leukotrien
implic
virusinduc
wheez
ill
common
cold
alon
clinic
trial
leukotrien
antagonist
virusinduc
wheez
ill
way
cromolyn
antiallerg
antiinflammatori
drug
effect
mast
cell
eosinophil
epitheli
cell
sensori
nerv
two
current
clinic
use
mechan
action
thought
involv
inhibit
chlorid
channel
intranas
nedocromil
sodium
reduc
symptom
review
question
futur
research
singl
combin
effect
treatmentvaccin
design
combat
numer
agent
caus
common
cold
treatment
common
cold
found
effect
enough
treat
cold
normal
individu
develop
symptom
aim
prophylaxi
atrisk
popul
would
appropri
formul
combin
alreadi
exist
remedi
effect
treatment
common
cold
new
molecular
techniqu
help
design
new
treatment
combat
respiratori
viral
infect
exampl
defin
common
import
molecular
mechan
find
way
block
newer
vaccin
strategi
exampl
recombin
dna
vaccin
abl
select
induc
protect
rather
immunopathogen
respons
antivir
resist
prove
great
problem
antivir
therapi
antimicrobi
therapi
improv
psychomotor
perform
subject
experiment
cold
recent
studi
intranas
inhal
sodium
cromoglyc
adult
common
cold
symptom
less
h
show
treatment
cromoglyc
day
produc
swifter
resolut
symptom
reduc
sever
symptom
last
day
treatment
addit
treatment
well
toler
signific
side
effect
studi
encourag
show
effect
symptom
begun
howev
mechan
involv
protect
effect
current
unknown
recent
gwaltney
propos
effect
suppress
common
cold
symptom
combin
antivir
antiinflammatori
effect
would
requir
neither
agent
appear
effect
administ
intranas
ifn
combin
intranas
ipratropium
anticholinerg
drug
oral
naproxen
nonsteroid
antiinflammatori
drug
h
experiment
rhinoviru
infect
viru
shed
mean
viru
titr
significantli
reduc
thu
signifi
antivir
effect
number
clinic
cold
mean
symptom
score
mucu
secret
cough
gener
malais
significantli
reduc
treat
subject
medic
well
toler
interestingli
symptom
least
effect
treat
studi
sneez
howev
antihistamin
effect
treat
sneez
allerg
rhiniti
addit
cocktail
may
render
effect
molecular
biolog
tool
increas
knowledg
respiratori
virolog
immunolog
enorm
suggest
sever
avenu
may
profit
explor
search
new
treatment
follow
identif
sever
cell
surfac
protein
act
viru
receptor
involv
viru
entri
cell
effort
target
block
virusreceptor
bind
one
particular
focu
attent
rhinoviru
bind
receptor
rhinovirus
block
interact
would
treat
common
cold
review
ref
trial
monoclon
antibodi
solubl
vitro
anim
studi
encourag
clinic
studi
compound
plan
way
howev
possibl
risk
emerg
resist
strain
taken
account
although
thought
mutat
produc
resist
would
result
nonviabl
receptor
bind
essenti
step
viru
replic
report
select
strain
rhinoviru
resist
neutral
solubl
receptor
vitro
sl
combin
detail
knowledg
viru
protein
chemistri
structur
highpow
comput
techniqu
lead
develop
new
antivir
compound
sever
exampl
new
antirhinovir
drug
develop
follow
identif
small
hydrophob
pocket
within
canyon
region
coat
protein
rhinovirus
tabl
region
import
viru
receptor
bind
uncoat
cell
entri
achiev
drug
fit
within
pocket
synthes
aid
comput
model
techniqu
stabil
coat
protein
thu
prevent
uncoat
releas
viral
rna
replic
compound
clinic
trial
long
known
virusspecif
strand
dna
rna
complementari
viral
messeng
genom
rna
anneal
viral
rna
virusinfect
cell
produc
antivir
effect
princip
mode
action
appear
rna
degrad
via
rnase
h
inhibit
rsv
replic
shown
vitro
use
oligonucleotid
direct
singlestrand
region
rsv
polymeras
l
gene
sz
pathway
involv
antivir
action
interferon
concept
design
enhanc
effici
antisens
oligonucleotid
vivo
specif
har
activ
ubiquit
intracellular
rnase
call
rnase
rnase
l
strategi
activ
rnase
conjug
antisens
oligonucleotid
specif
viral
target
result
highli
specif
effici
cleavag
viral
rna
studi
vitro
shown
system
work
nonvir
rna
target
viral
target
current
studi
recent
discov
picornavirus
includ
rhinovirus
human
coronaviru
similar
proteinas
share
sever
structur
function
characterist
proteinas
review
process
purifi
detail
structur
function
determin
one
attract
proposit
would
develop
antagonist
function
activ
proteinas
would
singl
compound
capabl
treat
common
cold
analog
rhinovirus
tcell
respons
influenza
virus
also
conserv
across
differ
viru
strain
gener
tcell
respons
normal
requir
endogen
express
antigen
occur
natur
infect
recent
studi
shown
plasmid
dna
encod
nucleocapsid
protein
influenza
type
evok
specif
tcell
respons
inject
skelet
muscl
mice
also
protect
subsequ
challeng
heterolog
strain
influenza
st
clearli
long
way
go
vaccin
suitabl
use
human
develop
potenti
excit
cure
common
cold
still
long
way
howev
effect
treatment
becom
avail
product
approach
like
target
popul
risk
elderli
young
signific
addit
respiratori
diseas
asthma
chronic
bronchiti
like
benefit
treatment
also
group
like
motiv
take
treatment
correctli
therebi
give
greatest
chanc
success
current
case
influenza
vaccin
strategi
encourag
concentr
treatment
prophylaxi
regimen
time
year
risk
greatest
winter
month
particular
week
children
return
school
holidayssl
perhap
except
influenza
vaccin
success
term
prevent
treatment
common
cold
far
evad
research
develop
major
barrier
develop
effect
treatment
multipl
agent
involv
difficulti
drug
deliveri
potenc
toxic
fact
viral
replic
peak
first
day
symptom
emerg
drugresist
strain
howev
newer
molecular
method
better
understand
viral
immunolog
lead
encourag
develop
vaccin
research
develop
morepot
antagonist
